Filing Details
- Accession Number:
- 0000899243-17-025463
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-11-06 19:45:01
- Reporting Period:
- 2017-11-06
- Accepted Time:
- 2017-11-06 19:45:01
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1624658 | Allena Pharmaceuticals Inc. | ALNA | () | E9 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1407577 | L.p. Institutional Vii Partners Venture Bessemer | C/O Bessemer Venture Partners 1865 Palmer Avenue, Suite 104 Larchmont NY 10538 | No | No | Yes | No | |
1459524 | Bvp Vii Special Opportunity Fund Lp | C/O Bessemer Venture Partners 1865 Palmer Avenue, Suite 104 Larchmont NY 10538 | No | No | Yes | No | |
1534338 | L.p. Vii Partners Venture Bessemer | C/O Bessemer Venture Partners 1865 Palmer Avenue, Suite 104 Larchmont NY 10538 | No | No | Yes | No | |
1540726 | Deer Vii & Co. Ltd. | C/O Bessemer Venture Partners 1865 Palmer Avenue, Suite 104 Larchmont NY 10538 | No | No | Yes | No | |
1540731 | Deer Vii & Co. L.p. | C/O Bessemer Venture Partners 1865 Palmer Avenue, Suite 104 Larchmont NY 10538 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-11-06 | 2,227,365 | $0.00 | 2,227,365 | No | 4 | C | Indirect | See Footnotes |
Common Stock | Acquisiton | 2017-11-06 | 36,000 | $14.00 | 2,263,365 | No | 4 | P | Indirect | See Footnotes |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See Footnotes |
No | 4 | P | Indirect | See Footnotes |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series A Preferred Stock | Disposition | 2017-11-06 | 6,122,448 | $0.00 | 1,466,800 | $0.00 |
Common Stock | Series B Preferred Stock | Disposition | 2017-11-06 | 3,174,603 | $0.00 | 760,565 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Footnotes
- Represents the total shares received by Bessemer Venture Partners VII Institutional L.P. ("BVP VII Inst"), Bessemer Venture Partners VII, L.P. ("BVP VII") and BVP VII Special Opportunity Fund L.P. ("BVP VII SOF" and together with BVP VII Inst and BVP VII, collectively, the "Funds") upon conversion of the Series A Preferred Stock and Series B Preferred Stock upon closing of the Issuer's initial public offering. Following the reported transaction, BVP VII Inst, BVP VII and BVP VII SOF owned 311,829 shares, 712,757 shares and 1,202,779 shares of Common Stock, respectively.
- The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 4.174-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
- Deer VII & Co. Ltd. ("Deer Ltd.") is the general partner of Deer VII & Co. L.P. ("Deer L.P."), which is the general partner of BVP VII Inst, BVP VII and BVP VII SOF. Deer Ltd. and Deer L.P. disclaim beneficial ownership of the securities held by the Funds, and this report shall not be deemed an admission that Deer Ltd. and Deer L.P. are the beneficial owners of such securities, except to the extent of their pecuniary interest therein, if any, by virtue of their direct and indirect general partner interests in the Funds.
- On November 6, 2017, BVP VII Inst, BVP VII and BVP VII SOF purchased 5,040 shares, 11,520 shares and 19,440 shares of Common Stock, respectively, at a price per share of $14.00 in the Issuer's initial public offering. Following the reported transaction, BVP VII Inst, BVP VII and BVP VII SOF owned 316,869 shares, 724,277 shares and 1,222,219 shares of Common Stock, respectively.
- Prior to the conversion, BVP VII Inst, BVP VII and BVP VII SOF owned 857,143 shares, 1,959,184 shares and 3,306,121 shares of Series A Preferred Stock, respectively.
- Prior to the conversion, BVP VII Inst, BVP VII and BVP VII SOF owned 205,350 shares, 469,376 shares, and 792,074 shares, respectively, of Common Stock issuable upon conversion of the Series A Preferred Stock.
- Prior to the conversion, BVP VII Inst, BVP VII and BVP VII SOF owned 444,444 shares, 1,015,873 shares and 1,714,286 shares of Series B Preferred Stock, respectively.
- Prior to the conversion, BVP VII Inst, BVP VII, and BVP VII SOF owned 106,479 shares, 243,381 shares, and, 410,705 shares, respectively, of Common Stock issuable upon conversion of the Series B Preferred Stock.